Skip to main content
. Author manuscript; available in PMC: 2011 Nov 15.
Published in final edited form as: Cancer Res. 2010 Nov 2;70(22):9185–9196. doi: 10.1158/0008-5472.CAN-10-1545

Figure 7. The phospho-status of SRp30a regulates Casp9 RNA splicing.

Figure 7

A,B,C) RT-PCR analysis of A, C) Casp9 minigene-derived transcripts or B, D) endogenous Casp9 splice variants from A549s transfected with the A) Casp9 minigene and SRp30a-WT or SRp30a-RD, B) SRp30a-WT or SRp30a-RD, C,D) the indicated SRp30a phospho-mutants. E,F,G,H) Western blot analysis of the phosphorylation state of SRp30a. Lysates were analyzed for the expression/migration of T7-tagged SRp30a. E) A549s were transfected with the indicated T7-tagged SRp30a constructs and total cell lysates were incubated in the presence of either active or denatured alkaline phosphatase (AP). F) HBEC-3KT and A549 cells transfected with the indicated T7-tagged SRp30a constructs. G) Endogenous SRp30a from A549 cells treated with 0.1% DMSO or erlotinib [50μM] for 48hr. Total protein lysates were incubated in the presence of either active or denatured alkaline phosphatase (AP). H) Endogenous SRp30a from A549 cells treated with 0.1% DMSO or Akt VIII [50μM]. I) RT-PCR analysis of endogenous Casp9 splice variants from A549s transfected with SRp30a-WT or SRp30a-QD ± Akt inhibitor VIII [25μM]. Data are expressed as means ± S.E.